BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

445 related articles for article (PubMed ID: 11483332)

  • 1. Serum PSA evaluations during salvage radiotherapy for post-prostatectomy biochemical failures as prognosticators for treatment outcomes.
    Do T; Dave G; Parker R; Kagan AR
    Int J Radiat Oncol Biol Phys; 2001 Aug; 50(5):1220-5. PubMed ID: 11483332
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Salvage radiotherapy for biochemical and clinical failures following radical prostatectomy.
    Do T; Parker RG; Do C; Tran L; Do L; Dolkar D
    Cancer J Sci Am; 1998; 4(5):324-30. PubMed ID: 9815297
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preirradiation PSA predicts biochemical disease-free survival in patients treated with postprostatectomy external beam irradiation.
    Crane CH; Rich TA; Read PW; Sanfilippo NJ; Gillenwater JY; Kelly MD
    Int J Radiat Oncol Biol Phys; 1997 Oct; 39(3):681-6. PubMed ID: 9336150
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment results of adjuvant radiotherapy and salvage radiotherapy after radical prostatectomy for prostate cancer.
    Wadasaki K; Kaneyasu Y; Kenjo M; Matsuura K; Murakami Y; Hashimoto Y; Ito K; Kiriu H; Ito A
    Int J Clin Oncol; 2007 Feb; 12(1):37-41. PubMed ID: 17380439
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Salvage radiotherapy for men with isolated rising PSA or locally palpable recurrence after radical prostatectomy: do outcomes differ?
    MacDonald OK; Schild SE; Vora S; Andrews PE; Ferrigni RG; Novicki DE; Swanson SK; Wong WW
    Urology; 2004 Oct; 64(4):760-4. PubMed ID: 15491716
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term outcome of patients with prostate cancer and pathologic seminal vesicle invasion (pT3b): effect of adjuvant radiotherapy.
    Lee HM; Solan MJ; Lupinacci P; Gomella LG; Valicenti RK
    Urology; 2004 Jul; 64(1):84-9. PubMed ID: 15245941
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial.
    Carrie C; Hasbini A; de Laroche G; Richaud P; Guerif S; Latorzeff I; Supiot S; Bosset M; Lagrange JL; Beckendorf V; Lesaunier F; Dubray B; Wagner JP; N'Guyen TD; Suchaud JP; Créhange G; Barbier N; Habibian M; Ferlay C; Fourneret P; Ruffion A; Dussart S
    Lancet Oncol; 2016 Jun; 17(6):747-756. PubMed ID: 27160475
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy.
    Kupelian PA; Katcher J; Levin HS; Klein EA
    Int J Radiat Oncol Biol Phys; 1997 Mar; 37(5):1043-52. PubMed ID: 9169811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preliminary results of three-dimensional conformal radiotherapy as salvage treatment for a rising prostate-specific antigen level postprostatectomy.
    Wilder RB; Hsiang JY; Ji M; Earle JD; de Vere White R
    Am J Clin Oncol; 2000 Apr; 23(2):176-80. PubMed ID: 10776980
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of hypofractionation and standard fractionation for post-prostatectomy salvage radiotherapy in patients with persistent PSA: single institution experience.
    Murgic J; Jaksic B; Prpic M; Kust D; Bahl A; Budanec M; Prgomet Secan A; Franco P; Kruljac I; Spajic B; Babic N; Kruslin B; Zovak M; Zubizarreta E; Rosenblatt E; Fröbe A
    Radiat Oncol; 2021 May; 16(1):88. PubMed ID: 33980277
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant hormone therapy before salvage radiotherapy for an increasing post-radical prostatectomy serum prostate specific antigen level.
    Tiguert R; Rigaud J; Lacombe L; Laverdière J; Fradet Y
    J Urol; 2003 Aug; 170(2 Pt 1):447-50. PubMed ID: 12853796
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved biochemical outcome with adjuvant radiotherapy after radical prostatectomy for prostate cancer with poor pathologic features.
    Vargas C; Kestin LL; Weed DW; Krauss D; Vicini FA; Martinez AA
    Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):714-24. PubMed ID: 15708249
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
    Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
    BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate-specific antigen doubling time subsequent to radical prostatectomy is a predictor of outcome following salvage external beam radiation therapy: a single-centre experience.
    Servoll E; Sæter T; Vlatkovic L; Nesland JM; Waaler G; Axcrona K
    Scand J Urol; 2015 Jun; 49(3):218-23. PubMed ID: 25428750
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial.
    Parker CC; Clarke NW; Cook AD; Kynaston HG; Petersen PM; Catton C; Cross W; Logue J; Parulekar W; Payne H; Persad R; Pickering H; Saad F; Anderson J; Bahl A; Bottomley D; Brasso K; Chahal R; Cooke PW; Eddy B; Gibbs S; Goh C; Gujral S; Heath C; Henderson A; Jaganathan R; Jakobsen H; James ND; Kanaga Sundaram S; Lees K; Lester J; Lindberg H; Money-Kyrle J; Morris S; O'Sullivan J; Ostler P; Owen L; Patel P; Pope A; Popert R; Raman R; Røder MA; Sayers I; Simms M; Wilson J; Zarkar A; Parmar MKB; Sydes MR
    Lancet; 2020 Oct; 396(10260):1413-1421. PubMed ID: 33002429
    [TBL] [Abstract][Full Text] [Related]  

  • 16. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores.
    Kupelian P; Katcher J; Levin H; Zippe C; Suh J; Macklis R; Klein E
    Cancer J Sci Am; 1997; 3(2):78-87. PubMed ID: 9099457
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term outcomes after high-dose postprostatectomy salvage radiation treatment.
    Goenka A; Magsanoc JM; Pei X; Schechter M; Kollmeier M; Cox B; Scardino PT; Eastham JA; Zelefsky MJ
    Int J Radiat Oncol Biol Phys; 2012 Sep; 84(1):112-8. PubMed ID: 22300563
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypofractionated radiotherapy as salvage for rising prostate-specific antigen after radical prostatectomy.
    Lee LW; McBain CA; Swindell R; Wylie JP; Cowan RA; Logue JP
    Clin Oncol (R Coll Radiol); 2004 Dec; 16(8):517-22. PubMed ID: 15630843
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Salvage radiotherapy for biochemical failure of radical prostatectomy: a single-institution experience.
    Liauw SL; Webster WS; Pistenmaa DA; Roehrborn CG
    Urology; 2003 Jun; 61(6):1204-10. PubMed ID: 12809898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Treatment results of salvage radiotherapy for biochemical recurrence after radical prostatectomy].
    Hatano K; Kinouchi T; Kinoshita T; Kobayashi M; Inoue H; Takada T; Hara T
    Nihon Hinyokika Gakkai Zasshi; 2009 Nov; 100(7):671-8. PubMed ID: 19999131
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.